Welcome to Strike Pharma! Using proprietary Adaptable Drug Affinity Conjugate (ADAC) technology, we aim to take precision medicine to a new level, enabling development of individualized immunotherapeutic treatments based on the genetic profile of each patient’s tumor. Such highly targeted treatments offer the potential to increase therapeutic efficacy and reduce dosage levels thereby minimizing the risk of side effects.
To date, development of immunotherapeutic cancer vaccines has mainly focused on identifying subtle differences present in the tumor microenvironment with the aim of creating a single entity, such as a peptide or antibody, that can be used as a vaccine. However, efficient, targeted delivery and in vivo stability have largely been ignored leading to limited success in the clinic. At Strike Pharma we aim to overcome these challenges.
Recent News & Events
Strike Pharma begins expansion of management team
Appoints Lindvi Gudmunsdotter as Director, Non-Clinical Development
Strike Pharma, Uppsala University and KTH Royal Institute of Technology present at CIMT 2022
CD40 agonistic, bispecific antibody candidates developed using ADAC technology ensure T-cell activation
Strike Pharma and Uppsala University present at AACR 2022
New data demonstrates proof of concept for ADAC technology platform
Strike Pharma completes 45 MSEK financing round
Efforts now focus on bringing first candidate to clinical trials and further development of ADAC technology platform
Strike raises SEK 10M (>1M $)
Swedish immuno-oncology newcomer STRIKE Pharma raises SEK 10 million for development of individualized solid tumour therapy.